You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

28 Items
Nov 2019
Updated
Feb 2020
Other Name(s): Procytox®
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
Jun 2019
Other Name(s): Cosmegen®
Jun 2019
Other Name(s): Xgeva® ()
Funding:
Exceptional Access Program
  • denosumab - Bony metastases in hormone refractory prostate cancer, with specific criteria
New Drug Funding Program
  • Denosumab - Hormone Refractory Prostate Cancer
Jul 2018
Other Name(s): Taxotere®
Funding:
New Drug Funding Program
  • Docetaxel - Metastatic Castration-Resistant Prostate Cancer
  • Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
  • Docetaxel - Metastatic Breast Cancer
  • Docetaxel - Hormone Sensitive Prostate Cancer
  • Docetaxel - CYCLDOCE for Early Operable Breast Cancer
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
Dec 2019
Other Name(s): Adriamycin®
Sep 2019
Other Name(s): Pharmorubicin PFS®
Funding:
New Drug Funding Program
  • Epirubicin - Adjuvant Treatment for Breast Cancer
  • Epirubicin - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
Aug 2019
Other Name(s): Vepesid®
Funding:
ODB - General Benefit
  • etoposide - oral capsules
Sep 2019
Other Name(s): Neupogen®; Grastofil®
Funding:
ODB - General Benefit
  • filgrastim - Grastofil brand is a general benefit
ODB Limited Use
  • filgrastim - (Neupogen brand) - Pre-Stem Cell Transplant Mobilization: For peripheral blood progenitor cell collection for peripheral stem cell transplant as treatment for malignant disease. Approval for Neupogen 300 mcg and 480 mcg vial format only.
  • filgrastim - (Neupogen brand) For pediatric patients (less than 18 years age) who are unable to achieve the appropriate dose of granulocyte colony-stimulating factor with the formulary listed formats of pre-filled syringes. Approval for Neupogen 300 mcg vial format only.
  • filgrastim - (Neupogen brand) For patients who are unable to use available formats of Grastofil due to a documented latex allergy. Approval for Neupogen 300 mcg and 480 mcg vial format only.
Sep 2019
Other Name(s): Gemzar® (multiple brands available)
Funding:
New Drug Funding Program
  • Gemcitabine - Carcinoma of Bladder or Urothelium
  • Gemcitabine - Non-Small Cell Lung Cancer (NSCLC)
  • Gemcitabine - Advanced Pancreatic Cancer
Feb 2018
Other Name(s): Ifex® (multiple brands available)
Aug 2016